Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer
Open Access
- 29 August 2011
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 22 (10) , 2286-2293
Abstract
Background: Cross-sectional studies showed that treatment with cisplatin chemotherapy for testicular cancer is associated with an increased incidence of cardiac dysfunction. We investigated longitudinal progression of and contributing factors to cardiac dysfunction in testicular cancer survivors. Patients and methods: Cardiac assessments were carried out before 10 months (range 7–15 months) and 6.9 years (range 4.9–9.7 years) after start of cisplatin-based chemotherapy, consisting of echocardiography [systolic function (left ventricular ejection fraction, LVEF), diastolic function (myocardial tissue velocities; tissue velocity imaging of early diastole, TVI Et)] and plasma biomarkers (N-Terminal pro brain natriuretic peptide, NT-proBNP; galectin-3). Results: In 37 patients [median age 34 years (range 24–51 years)], the incidence of abnormal TVI Et increased from 0% at baseline and 4.5% at 10 months (in 27 patients) to 16.7% at 6.9 years post-chemotherapy (P = 0.03). One patient developed LVEF Conclusions: In this longitudinal cohort study, we observed a gradual decline in diastolic parameters after cisplatin-based chemotherapy for testicular cancer, whereas the rate of systolic dysfunction remains low. The association of larger declines in diastolic parameters with hypertension and obesity stresses the need to monitor and treat cardiovascular risk factors.Keywords
Funding Information
- Dutch Cancer Society (2009-4365)
This publication has 31 references indexed in Scilit:
- Testicular Cancer Survivorship: Research Strategies and RecommendationsJNCI: Journal of the National Cancer Institute, 2010
- Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancerBritish Journal of Cancer, 2009
- Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?Journal of Clinical Oncology, 2008
- Medical Treatment of Advanced Testicular CancerJAMA, 2008
- Treatment-Specific Risks of Second Malignancies and Cardiovascular Disease in 5-Year Survivors of Testicular CancerJournal of Clinical Oncology, 2007
- Left ventricular and cardiac autonomic function in survivors of testicular cancerEuropean Journal of Clinical Investigation, 2005
- Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular CancerJournal of Clinical Oncology, 2003
- New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part ICirculation, 2002
- Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancerAnnals of Oncology, 2002
- Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular CancerJournal of Clinical Oncology, 2000